Overview

• BioNTech has offered to swap each Curevac share for American Depositary Shares, valuing the transaction at $1.25 billion (about $5.46 per share).
• So far investors controlling 50.08% of Curevac’s stock have agreed to the takeover, ahead of the 80% acceptance threshold required to close the deal.
• The German government and state-backed lender KfW have expressed general support for the offer and are expected to back the transaction.
• BioNTech has pledged to preserve Curevac’s Tübingen research and development hub to strengthen Germany’s biotech ecosystem.
• The company aims to leverage Curevac’s mRNA expertise for its first US cancer therapy approval submission by the end of 2025.